What is the Origin of CJC-1295 Ipamorelin Combination?

Both peptides were developed in the field of peptide chemistry and endocrinology research to treat GH deficiency and its associated catabolic states. CJC-1295 was designed with Drug Affinity Complex (DAC) technology to extend its half-life, while Ipamorelin was created as a selective GH secretagogue with minimal impact on cortisol or prolactin release. Their combined use in clinical practice leverages their distinct yet complementary mechanisms for maximum therapeutic effect.

What is the Mechanism of CJC-1295 Ipamorelin Combination?

CJC-1295 binds to and activates the GHRH receptors on the pituitary somatotroph cells, providing a long-acting signal for GH release. Ipamorelin, conversely, acts as a ghrelin mimetic, binding to the Growth Hormone Secretagogue Receptor (GHSR) to stimulate a natural pulse of GH secretion. The combined action of these two agents mimics the body's physiological, pulsatile release pattern more effectively than single-agent therapy, ensuring a sustained elevation of circulating GH and downstream IGF-1.

CJC-1295 Ipamorelin Combination

Meaning

The CJC-1295 Ipamorelin Combination is a synergistic therapeutic protocol involving two synthetic peptides: CJC-1295, a Growth Hormone-Releasing Hormone (GHRH) analog, and Ipamorelin, a Growth Hormone Secretagogue (GHS). This combination is clinically utilized to promote a sustained, pulsatile increase in endogenous growth hormone (GH) secretion from the anterior pituitary gland. The goal is to safely and physiologically elevate GH and Insulin-like Growth Factor-1 (IGF-1) levels, often to support tissue repair, improve body composition, and enhance recovery.